Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association

(2020) Salim S. Virani et al.   CIRCULATION

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER

(2018) Marc S. Sabatine et al.   CIRCULATION

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

(2017) Robert P Giugliano et al.   LANCET

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

(2017) Marc P. Bonaca et al.   CIRCULATION

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

(2016) Marc S. Sabatine et al.   AMERICAN HEART JOURNAL

Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults

(2016) Dick C. Chan et al.   Heart Lung and Circulation

Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study

(2016) Wuxiang Xie et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome

(2016) Sabina A. Murphy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis

(2015) A. K. Pandit et al.   ACTA NEUROLOGICA SCANDINAVICA

Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?

(2015) Robert P. Giugliano et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

(2014) Walter N. Kernan et al.   STROKE

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   CIRCULATION

Cholesterol Levels and Risk of Hemorrhagic Stroke

(2013) Xiang Wang et al.   STROKE

Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin

(2011) Antonio Eduardo P. Pesaro et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles

(2009) Giuseppe Danilo Norata et al.   ATHEROSCLEROSIS

Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention

(2009) Pierre Amarenco et al.   LANCET NEUROLOGY